The Increasing Trend of Type 2 Diabetes in Youth: An Overview
The EMAs drug safety committee (PRAC) launched a review of medicines containing semaglutide a GLP-1 agonist and the active ingredient in Novo Nordisk's Ozempic, Wegovy and Rybelsus in January, following concerns that the drugs could lead to an increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION)
But while seemingly effective for shedding pounds and addressing other health issues typically connected to obesity the concern that weight-loss drugs like Ozempic, Rybelsus and Wegovy might be linked to thyroid cancer has been maybe they do, maybe they don't
And so you're gonna hear that, you can read about all those things
Obesity increases the risk of developing atrial fibrillation by 50%
Het Wegovy- merk van semaglutide is nu goedgekeurd voor gewichtsverlies bij patinten met obesitas of overgewicht (overgewicht) die ook aan gewicht gerelateerde medische aandoeningen hebben, zoals hoge bloeddruk, diabetes type 2 of hoog cholesterol
